Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study.

Ruoxi HongWen XiaLiye WangKaping LeeQianyi LuKuikui JiangShengfeng LiJinquan YuJin WeiWeijia TangDanyang ZhouXin AnJiajia HuangCong XueXiwen BiYanxia ShiZhongyu YuanFei XuShu-Sen Wang

Published in: Cancer communications (London, England) (2021)

BAT8001 demonstrated favorable safety profiles, with promising anti-tumor activity in patients with HER2-positive locally advanced or metastatic breast cancer. BAT8001 has the potential to provide a new therapeutic option in patients with metastatic HER2-positive breast cancer.

Keyphrases

positive breast cancer
metastatic breast cancer
locally advanced
open label
squamous cell carcinoma
rectal cancer
neoadjuvant chemotherapy
radiation therapy
clinical trial
human health
risk assessment